Ind-Swift Laboratories Posts Strong Q1 FY27 Results; Operating EBITDA Rises 2.85x YoY

Ind-Swift Laboratories Posts Strong Q1 FY27 Results; Operating EBITDA Rises 2.85x YoY​

Ind-Swift Laboratories Limited, a global pharmaceutical formulations company operating in over 85 countries, has reported robust un-audited standalone financial results for the quarter ended June 30, 2026 (Q1 FY27). The company demonstrated significant growth in profitability and margins while strengthening its position as a debt-free formulations platform.

The Q1 performance saw substantial improvements across key metrics. Operating Income grew by 21.16%, with operating EBITDA increasing by 2.85x year-over-year (YoY). Concurrently, the operating EBITDA margin expanded significantly, reaching 17.91%. Net Profit After Tax (PAT), excluding exceptional items, also saw a strong increase of 2.04x YoY.

The financial performance highlights are detailed in the table below:

Operational and Growth Milestones​

Beyond the financial results, the company reported several strategic operational milestones during the quarter. Key among these was the commercialization of a partnership with Viatris (USA), Manx (UK), and Arrotex (Australia) in the CDMO space, which is expected to contribute an incremental ₹ 200 -220 crore of revenue in FY27.

Furthermore, Ind-Swift saw two products achieve commercial status: Ibuprofen Sachet for the European market, and Macrogol Sachet for the UK and Australia markets.

The company's global dossier pipeline also continued to expand. The number of dossiers filed rose to 2,100+ from 1,915+, while product registrations grew to 900+ from 750+.

Management Perspective and Future Strategy​

Mr. N.R. Munjal, Chairman of Ind-Swift Laboratories, commented that Q1 FY27 represented an excellent start to the year, underscoring the successful transformation of the company into a focused Finished Dosage Formulations (FDF) manufacturer. The improved EBITDA margin and PAT margins reflect better efficiencies, an improved business mix, and disciplined execution across the organization.

The planned upgrade of the Samba manufacturing facility to EU-GMP and PIC/S standards is highlighted as a key growth initiative. This investment is expected to strengthen their platform in regulated markets, support filings globally, enhance export opportunities, and expand participation in high-value CDMO programs.

Looking ahead, Ind-Swift has delineated clear strategic priorities for the coming fiscal years. Domestically, the focus remains on expanding its footprint into peninsular India and targeting high-growth chronic therapeutic categories with a target of 15 to 20% CAGR. Internationally, the company plans sustained own-brand growth, supported by increasing penetration in UAE and Central Asia, and ongoing programs with global partners.

The company expects FY27 to witness revenue growth exceeding 50%. In the medium term, Ind-Swift is confident of achieving a revenue CAGR above 20%, alongside an EBITDA margin expansion of 600 to 800 bps, driven by operating leverage and improved business mix.

The company's portfolio is further supported by its transformation into a net debt-free, pure-play formulations platform, backed by a robust dossier pipeline, established partnerships, and broad international presence.

INDSWFTLAB Stock Price Movement​

Ind-Swift Laboratories Limited shares surged on Wednesday, climbing to ₹301.99 after posting a robust 6.08% gain. This upward momentum saw the stock capture its 52-week high, amid trading activity involving 8,635,452 shares.